Recent studies have demonstrated that the combined use of platinum-based chemotherapeutic agents and PDE inhibitors have a higher antiproliferative effect on lung cancer cells than platinum monotherapy, the current standard of care (78, 82). The gene discussed is ALDH7A1; the disease is lung carcinoma.